Previous studies have demonstrated that loss of PTP1B protects against metabolic diseases such as myocardial anomalies, atherosclerotic plaque formation and diabetes by activating AMPK33–35, further confirming the correlation and interaction between PTP1B and AMPK. This evidence concerns the gene PTPN1 and metabolic disease.